New Weapon In The Arsenal Against HER-2 Positive Breast Cancer



Photo Credit:  Genetech

 The FDA recently approved a new drug developed by Roche pharamaceuticals for the treatment of HER-2 positive breast cancers.  Perjeta was accepted by the FDA for priority review, indicating that the drug presents a significant advantage over existing treatments.  During clinical trials for advanced breast cancer, the drug significantly delayed the cancer from worsening, compared to the existing standard of care. 

In addition to the approved Perjeta, Roche also is developing T-DM1, which is designed to combine a type of chemotherapy to Herceptin.  The drug is in Phase III trials and is being developed for treatment of HER-2 positive breast cancers. 

Read more:  http://www.cbsnews.com/8301-504763_162-57451906-10391704/fda-approves-perjeta-for-late-stage-breast-cancer/

Breakthrough In Triple Negative: DNA Marker Discovered

Researchers at the North Shore-LIJ Health System and the Feinstein Institute for Medical Research in New York have discovered a DNA marker linked to triple-negative breast cancer that's helping them to determine why African-American women often experience this more aggressive form of the disease. 

Read more about this exciting development:  http://www.huffingtonpost.com/2012/06/06/breast-cancer-genetics-race-therapy-treatment_n_1574724.html

We Have A New Look!

Please visit our website to see our new design!  Hope you like it:  

 www.triplepink.org